Protective effects of PARP inhibition on liver microcirculation and function after haemorrhagic shock and resuscitation in male rats - PubMed (original) (raw)

. 2006 Oct;32(10):1649-57.

doi: 10.1007/s00134-006-0335-y. Epub 2006 Aug 23.

Affiliations

• PMID: 16927075
• DOI: 10.1007/s00134-006-0335-y

Protective effects of PARP inhibition on liver microcirculation and function after haemorrhagic shock and resuscitation in male rats

J P Roesner et al. Intensive Care Med. 2006 Oct.

Abstract

Objective: The aim of this study was to investigate the impact of the water-soluble poly-(ADP)-ribose-polymerase (PARP) inhibitor 5-aminoisoquinolinone (5-AIQ) on liver microcirculation and function after haemorrhagic shock and resuscitation.

Design: Controlled, randomized animal study.

Setting: University animal care facility and research laboratory.

Subject: Male Sprague-Dawley rats were subjected to haemorrhagic shock for 1 h, followed by resuscitation with shed blood and crystalloid solution for a total of 5 h.

Interventions: The PARP inhibitor 5-AIQ (3 mg/kg; n=7) or vehicle (n=7) was administered 5 min prior to resuscitation. Sham-operated animals without induction of shock served as controls (n=7).

Measurements and results: Using intravital fluorescence microscopy hepatic microcirculation was assessed at baseline, end of shock phase as well as 1 h and 5 h after resuscitation. Systemic arterial blood pressure and bile flow were continuously monitored. 5-AIQ treatment attenuated shock/resuscitation-induced increase of intrahepatic leukocyte-endothelial cell interaction with a marked reduction of both sinusoidal leukostasis and venular leukocyte adherence. Moreover, nutritive perfusion was found improved, guaranteeing sufficient oxygen supply to tissue, as indicated by low NADH autofluorescence, which was not different to that in controls. Most notably, excretory liver function reached baseline level over 5 h of reperfusion in 5-AIQ-treated animals.

Conclusions: In the present setting of shock/resuscitation in male rats the PARP inhibitor 5-AIQ proved to be very effective in ameliorating compromised liver microcirculation and function. Further research has to confirm that PARP inhibition is a suitable tool in the acute treatment of patients suffering from reduced circulating blood volume and thus microcirculatory organ dysfunction.

PubMed Disclaimer

Comment in

• The world according to poly(ADP-ribose) polymerase (PARP)--update 2006.
  Barth E, Radermacher P, Szabó C. Barth E, et al. Intensive Care Med. 2006 Oct;32(10):1470-4. doi: 10.1007/s00134-006-0336-x. Epub 2006 Aug 23. Intensive Care Med. 2006. PMID: 16927074 No abstract available.

Similar articles

• Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock.
  McDonald MC, Mota-Filipe H, Wright JA, Abdelrahman M, Threadgill MD, Thompson AS, Thiemermann C. McDonald MC, et al. Br J Pharmacol. 2000 Jun;130(4):843-50. doi: 10.1038/sj.bjp.0703391. Br J Pharmacol. 2000. PMID: 10864891 Free PMC article.
• [Microcirculation of the liver in hemorrhagic shock in the rat and its significance for energy metabolism and function].
  Vollmar B, Lang G, Post S, Menger MD, Messmer K. Vollmar B, et al. Zentralbl Chir. 1993;118(4):218-25. Zentralbl Chir. 1993. PMID: 8493831 German.
• 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs).
  Threadgill MD. Threadgill MD. Curr Med Chem. 2015;22(33):3807-29. doi: 10.2174/0929867322666151002110602. Curr Med Chem. 2015. PMID: 26429070 Review.
• Hemorrhagic shock.
  Peitzman AB, Billiar TR, Harbrecht BG, Kelly E, Udekwu AO, Simmons RL. Peitzman AB, et al. Curr Probl Surg. 1995 Nov;32(11):925-1002. doi: 10.1016/s0011-3840(05)80008-5. Curr Probl Surg. 1995. PMID: 7587344 Review.

Cited by

• Inhibition of poly(adenosine diphosphate-ribose) polymerase attenuates ventilator-induced lung injury.
  Vaschetto R, Kuiper JW, Chiang SR, Haitsma JJ, Juco JW, Uhlig S, Plötz FB, Della Corte F, Zhang H, Slutsky AS. Vaschetto R, et al. Anesthesiology. 2008 Feb;108(2):261-8. doi: 10.1097/01.anes.0000299434.86640.15. Anesthesiology. 2008. PMID: 18212571 Free PMC article.
• PARP and PARG inhibitors--new therapeutic targets in cancer treatment.
  Fauzee NJ, Pan J, Wang YL. Fauzee NJ, et al. Pathol Oncol Res. 2010 Dec;16(4):469-78. doi: 10.1007/s12253-010-9266-6. Epub 2010 Apr 12. Pathol Oncol Res. 2010. PMID: 20383759 Review.
• The world according to poly(ADP-ribose) polymerase (PARP)--update 2006.
  Barth E, Radermacher P, Szabó C. Barth E, et al. Intensive Care Med. 2006 Oct;32(10):1470-4. doi: 10.1007/s00134-006-0336-x. Epub 2006 Aug 23. Intensive Care Med. 2006. PMID: 16927074 No abstract available.
• Age related changes in NAD+ metabolism oxidative stress and Sirt1 activity in wistar rats.
  Braidy N, Guillemin GJ, Mansour H, Chan-Ling T, Poljak A, Grant R. Braidy N, et al. PLoS One. 2011 Apr 26;6(4):e19194. doi: 10.1371/journal.pone.0019194. PLoS One. 2011. PMID: 21541336 Free PMC article. Retracted.
• Year in review in Intensive Care Medicine, 2006. I. Experimental studies. Clinical studies: brain injury, renal failure and endocrinology.
  Andrews P, Azoulay E, Antonelli M, Brochard L, Brun-Buisson C, De Backer D, Dobb G, Fagon JY, Gerlach H, Groeneveld J, Macrae D, Mancebo J, Metnitz P, Nava S, Pugin J, Pinsky M, Radermacher P, Richard C. Andrews P, et al. Intensive Care Med. 2007 Jan;33(1):49-57. doi: 10.1007/s00134-006-0501-2. Epub 2006 Dec 19. Intensive Care Med. 2007. PMID: 17180391 Review. No abstract available.

References

1. 1. Am J Pathol. 1994 Dec;145(6):1421-31 - PubMed
2. 1. Shock. 1999 Sep;12(3):188-95 - PubMed
3. 1. Microvasc Res. 1984 May;27(3):331-52 - PubMed
4. 1. Am J Physiol. 1994 Nov;267(5 Pt 1):G786-93 - PubMed
5. 1. J Trauma. 2000 Nov;49(5):879-85 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer